Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.

Trial Details

NCT ID
NCT07562152
Phase
PHASE3
Sponsor
Immuneering Corporation
Status
RECRUITING
Cancer Type
Pancreatic Ductal Adenocarcinoma Pancreatic Cancer
Interventions
  • Atebimetinib
  • GnP
  • mGnP
Locations (sample)
  • Phoenix, Arizona, United States|33.44838,-112.07404
  • Duarte, California, United States|34.13945,-117.97729
  • Newark, Delaware, United States|39.68372,-75.74966
  • Port Saint Lucie, Florida, United States|27.29393,-80.35033
  • Sarasota, Florida, United States|27.33643,-82.53065

Key Eligibility Criteria

  • Must be ≥18 years of age
  • Must have confirmed diagnosis according to AJCC staging as follows:
  • Metastatic pancreatic adenocarcinoma within 12 weeks prior to screening
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Ductal Adenocarcinoma Pancreatic Cancer Trials on Trialify →